News & events

News & events

Filter by:
  • Management TeamNews

VarmX announces appointment of John Glasspool as CEO

Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company...

  • Management TeamNews

VarmX announces appointment of Martijn Negen as COO

Leiden, The Netherlands, 10 september 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...

  • Conferences & Events

VarmX to Present Two Abstracts on Lead Compound, VMX-C001, at ISTH 2023 Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...
  • News

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has...
  • News

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • News

VarmX appoints Paul Roos as Chief Financial Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • Scientific publications

Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors

VMX-C001, a modified form of human zymogen factor X, is being developed to stop or prevent bleeding in patients taking...

  • News

VarmX to Present New Data at the 2022 ISTH Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announced it will...
  • News

First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Bypassing Agent, VMX-C001

VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of...
  • News

VarmX awarded funding from the EIC Accelerator

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has been awarded up...
  • News

VarmX to Present New Data on Lead Compound, VMX-C001, at the ISTH 2021 Virtual Congress

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio